NEDD4L and Miyoshi myopathy: To sum up, these findings, in addition to representing NEDD4L as a newly recognized autophagy activator, suggest both the application of NEDD4L as a new biomarker for predicting MM patients’ response to bortezomib as well as the usefulness of NEDD4L activators in combination with bortezomib as a novel therapeutic approach for the MM treatment.